Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion

Influenza vaccination can benefit most populations, including adults ≥ 65 years of age, who are at greater risk of influenza-related complications. In many countries, enhanced vaccines, such as adjuvanted, high-dose, and recombinant trivalent/quadrivalent influenza vaccines (aTIV/aQIV, HD-TIV/HD-QIV...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Postma, Maarten, Fisman, David, Giglio, Roberto, Márquez-Peláez, Sergio, Nguyen, Van Hung, Pugliese, Andrea, Ruíz-Aragón, Jesús, Urueña, Analía, Mould-Quevedo, Joaquín
Formato: Artículo
Lenguaje:Inglés
Publicado: 2024
Materias:
Costo efectividad
Influenza
Vacuna mejorada
Acceso en línea:https://doi.org/10.3390/vaccines11061089
http://repositorio.isalud.edu.ar/xmlui/handle/123456789/2043
Aporte de:
Repositorio Institucional Digital (RID ISALUD) de Universidad ISALUD
id I92-R382-123456789-2043
record_format dspace
spelling I92-R382-123456789-20432024-10-31T06:00:54Z Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion Postma, Maarten Fisman, David Giglio, Roberto Márquez-Peláez, Sergio Nguyen, Van Hung Pugliese, Andrea Ruíz-Aragón, Jesús Urueña, Analía Mould-Quevedo, Joaquín Costo efectividad Influenza Vacuna mejorada Influenza vaccination can benefit most populations, including adults ≥ 65 years of age, who are at greater risk of influenza-related complications. In many countries, enhanced vaccines, such as adjuvanted, high-dose, and recombinant trivalent/quadrivalent influenza vaccines (aTIV/aQIV, HD-TIV/HD-QIV, and QIVr, respectively), are recommended in older populations to provide higher immunogenicity and increased relative vaccine efficacy/effectiveness (rVE) than standard-dose vaccines. This review explores how efficacy and effectiveness data from randomized controlled trials and real-world evidence (RWE) are used in economic evaluations. Findings from published cost-effectiveness analyses (CEA) on enhanced influenza vaccines for older adults are summarized, and the assumptions and approaches used in these CEA are assessed alongside discussion of the importance of RWE in CEA. Results from many CEA showed that adjuvanted and high-dose enhanced vaccines were cost-effective compared with standard vaccines, and that differences in rVE estimates and acquisition price may drive differences in cost-effectiveness estimates between enhanced vaccines. Overall, RWE and CEA provide clinical and economic rationale for enhanced vaccine use in people ≥ 65 years of age, an at-risk population with substantial burden of disease. Countries that consider RWE when making vaccine recommendations have preferentially recommended aTIV/aQIV, as well as HD-TIV/HD-QIV and QIVr, to protect older individuals. Fil: Urueña A. Centro de Estudios para la Prevención y Control de Enfermedades Transmisibles, Universidad Isalud, Venezuela 931, Ciudad Autónoma de Buenos Aires C1095AAS, Argentina 2024-10-30T19:26:49Z 2024-10-30T19:26:49Z 2023 Article Postma M, Fisman D, Giglio N, Márquez-Peláez S, Nguyen VH, Pugliese A, Ruiz-Aragón J, Urueña A, Mould-Quevedo J. Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion. Vaccines. 2023; 11(6):1089. https://doi.org/10.3390/vaccines11061089 https://doi.org/10.3390/vaccines11061089 http://repositorio.isalud.edu.ar/xmlui/handle/123456789/2043 en application/pdf
institution Universidad ISALUD
institution_str I-92
repository_str R-382
collection Repositorio Institucional Digital (RID ISALUD)
language Inglés
topic Costo efectividad
Influenza
Vacuna mejorada
spellingShingle Costo efectividad
Influenza
Vacuna mejorada
Postma, Maarten
Fisman, David
Giglio, Roberto
Márquez-Peláez, Sergio
Nguyen, Van Hung
Pugliese, Andrea
Ruíz-Aragón, Jesús
Urueña, Analía
Mould-Quevedo, Joaquín
Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion
topic_facet Costo efectividad
Influenza
Vacuna mejorada
description Influenza vaccination can benefit most populations, including adults ≥ 65 years of age, who are at greater risk of influenza-related complications. In many countries, enhanced vaccines, such as adjuvanted, high-dose, and recombinant trivalent/quadrivalent influenza vaccines (aTIV/aQIV, HD-TIV/HD-QIV, and QIVr, respectively), are recommended in older populations to provide higher immunogenicity and increased relative vaccine efficacy/effectiveness (rVE) than standard-dose vaccines. This review explores how efficacy and effectiveness data from randomized controlled trials and real-world evidence (RWE) are used in economic evaluations. Findings from published cost-effectiveness analyses (CEA) on enhanced influenza vaccines for older adults are summarized, and the assumptions and approaches used in these CEA are assessed alongside discussion of the importance of RWE in CEA. Results from many CEA showed that adjuvanted and high-dose enhanced vaccines were cost-effective compared with standard vaccines, and that differences in rVE estimates and acquisition price may drive differences in cost-effectiveness estimates between enhanced vaccines. Overall, RWE and CEA provide clinical and economic rationale for enhanced vaccine use in people ≥ 65 years of age, an at-risk population with substantial burden of disease. Countries that consider RWE when making vaccine recommendations have preferentially recommended aTIV/aQIV, as well as HD-TIV/HD-QIV and QIVr, to protect older individuals.
format Article
author Postma, Maarten
Fisman, David
Giglio, Roberto
Márquez-Peláez, Sergio
Nguyen, Van Hung
Pugliese, Andrea
Ruíz-Aragón, Jesús
Urueña, Analía
Mould-Quevedo, Joaquín
author_facet Postma, Maarten
Fisman, David
Giglio, Roberto
Márquez-Peláez, Sergio
Nguyen, Van Hung
Pugliese, Andrea
Ruíz-Aragón, Jesús
Urueña, Analía
Mould-Quevedo, Joaquín
author_sort Postma, Maarten
title Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion
title_short Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion
title_full Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion
title_fullStr Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion
title_full_unstemmed Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion
title_sort real-world evidence in cost-effectiveness analysis of enhanced influenza vaccines in adults ≥ 65 years of age: literature review and expert opinion
publishDate 2024
url https://doi.org/10.3390/vaccines11061089
http://repositorio.isalud.edu.ar/xmlui/handle/123456789/2043
work_keys_str_mv AT postmamaarten realworldevidenceincosteffectivenessanalysisofenhancedinfluenzavaccinesinadults65yearsofageliteraturereviewandexpertopinion
AT fismandavid realworldevidenceincosteffectivenessanalysisofenhancedinfluenzavaccinesinadults65yearsofageliteraturereviewandexpertopinion
AT giglioroberto realworldevidenceincosteffectivenessanalysisofenhancedinfluenzavaccinesinadults65yearsofageliteraturereviewandexpertopinion
AT marquezpelaezsergio realworldevidenceincosteffectivenessanalysisofenhancedinfluenzavaccinesinadults65yearsofageliteraturereviewandexpertopinion
AT nguyenvanhung realworldevidenceincosteffectivenessanalysisofenhancedinfluenzavaccinesinadults65yearsofageliteraturereviewandexpertopinion
AT puglieseandrea realworldevidenceincosteffectivenessanalysisofenhancedinfluenzavaccinesinadults65yearsofageliteraturereviewandexpertopinion
AT ruizaragonjesus realworldevidenceincosteffectivenessanalysisofenhancedinfluenzavaccinesinadults65yearsofageliteraturereviewandexpertopinion
AT uruenaanalia realworldevidenceincosteffectivenessanalysisofenhancedinfluenzavaccinesinadults65yearsofageliteraturereviewandexpertopinion
AT mouldquevedojoaquin realworldevidenceincosteffectivenessanalysisofenhancedinfluenzavaccinesinadults65yearsofageliteraturereviewandexpertopinion
_version_ 1831499716605509632

Ejemplares similares